4DMT Appoints Kristian Humer as Chief Financial Officer

Core Insights - 4D Molecular Therapeutics has appointed Kristian Humer as Chief Financial Officer to lead financial strategy and operations [1][2][3] - The company is advancing multiple Phase 3 programs and preparing for commercial readiness, indicating a critical stage in its development [3][4] Company Overview - 4D Molecular Therapeutics is a late-stage biotechnology company focused on durable and disease-targeted therapeutics, aiming to transform treatment paradigms [1][4] - The lead product candidate, 4D-150, targets blinding retinal vascular diseases and is currently in Phase 3 development for wet age-related macular degeneration and diabetic macular edema [4] - The second product candidate, 4D-710, is a genetic medicine for cystic fibrosis, demonstrating successful delivery of the CFTR transgene [4] Leadership Background - Kristian Humer brings over 20 years of experience in corporate finance and healthcare investment banking, having held senior roles at Citi and served as CFO for other publicly traded companies [2][3] - His expertise is expected to enhance 4DMT's long-term growth and value creation for patients and shareholders [3]